Our Investment Story

Learn More

Learn about Roche and Genentech – how we create business and shareholder value, and how we are moving the industry forward in key areas like personalized healthcare

Fact Sheet

Learn about the combined global strengths from Roche and Genentech in biotechnology, pharmaceuticals, and diagnostics (PDF).

Living 10 Years in the Future

Mike Varney, head of Genentech Research and Early Development, explains how this culture of innovation is helping to solve some of the hardest biomedical problems of our time.

PD-L1/PD-1 Pathway: A Security Checkpoint‬

Dr. Dan Chen explains how immunotherapy may affect the PD-L1/PD-1 pathway, enabling the body to better detect and fight cancer.

Unconventional Wisdom

How challenging the status quo led to the discovery of the B cell as a new target in MS.

Understanding Manufacturing

What does it take to manufacture biologics?

How to Invest

Find out how you can own a part of Roche and Genentech as the group creates a future of personalized healthcare and scientific breakthroughs.

Our Pipeline

See the latest progress on differentiated medicines and therapies in development.

Stock Information

Current and past market data for Roche, including quotes and dividend history.

The Value of the Right Partner

Learn about the three most important factors a biotech company should consider when looking for a partner.

Latest Updates

Get the latest on Roche and Genentech initiatives.

Annual Reports

Review and download financial statements and the annual report.


View latest presentations from previous events.

Upcoming Events

Stay up to date on current IR events.

Frequently Asked Questions

Find answers to the questions often asked by investors.

Management Team

Meet the leadership team responsible for driving the next evolution of healthcare.
Load More  


For IR Requests:

Phone: +1 650 225 5566

Fax: +1 650 225 8326

For media inquiries:
Phone: +1 650 467 6800


This website contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for any current or future period will necessarily match or exceed the historical published earnings or earnings per share of Roche. Information accessed herein may not under any circumstances be used for the purpose of, or in connection with, the quotation of any securities on an automated inter-dealer quotation system within the meaning of Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Current Stock Price

Reasons to Invest

Years of combined expertise in biotech, pharma, and diagnostics.
New molecule entities in the pipeline.
years in a row of increased dividends.